BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 28033600)

  • 1. [Hyperkalemia - current therapuetic strategies].
    Głogowski T; Wojtaszek E
    Wiad Lek; 2016; 69(5):745-748. PubMed ID: 28033600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
    De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium binding for conservative and preservative management of chronic kidney disease.
    Clegg DJ; Palmer BF
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of hyperkalemia in chronic kidney disease.
    Cowan AC; Gharib EG; Weir MA
    Curr Opin Nephrol Hypertens; 2017 May; 26(3):235-239. PubMed ID: 28212180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Hyperkalemia: Stepping Into a New Frontier.
    Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
    J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
    Henneman A; Guirguis E; Grace Y; Patel D; Shah B
    Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapies for hyperkalemia.
    Leon SJ; Harasemiw O; Tangri N
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z; Peacock WF; LoVecchio F; Levy PD
    Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium zirconium cyclosilicate in hyperkalemia.
    Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
    N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on medical management of hyperkalemia.
    Lopes MB; Rocha PN; Pecoits-Filho R
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.